A review in The Lancet reveals that one in five people globally are genetically predisposed to higher levels of lipoprotein(a), increasing their risk of cardiovascular diseases. This lipid particle is a common genetic cause of heart attacks, strokes, and other cardiovascular issues. New medications are being developed to lower lipoprotein(a) levels by up to 98%, with promising results expected by 2026. Testing for lipoprotein(a) is easy and available, and expanding this globally can help identify individuals who could benefit from the medication. In the meantime, lifestyle changes such as exercise, healthy eating, and avoiding smoking can help manage the risk.
Source link
Significant global cardiovascular risk linked to high lipoprotein(a) levels
